ANG1005: Results of a phase I study in patients with advanced solid tumors and brain metastases.

John Sarantopoulos,Nashat Y. Gabrail,Stacy Moulder,Andrew Brenner,Carrie Smith,Danielle Bouchard,Kelly Elian,Betty Lawrence,Jean-Paul Castaigne,Razelle Kurzrock

ANG1005: Results of a phase I study in patients with advanced solid tumors and brain metastases.

2010

John Sarantopoulos
Nashat Y. Gabrail
Stacy Moulder
Andrew Brenner
Carrie Smith
Danielle Bouchard
Kelly Elian
Betty Lawrence
Jean-Paul Castaigne
Razelle Kurzrock

2556 Background: ANG1005 is a novel taxane derivative created from Angiochem's Engineered Peptide Compound (EPiC) platform shown to penetrate the blood-brain barrier (BBB) and tumor cells by target...

Keywords:

Pathology
ANG1005
Medicine
EPIC
phase i study
in patient
Cancer research
Peptide
tumor cells
Taxane derivative

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations